Morphic (MORF) Stock Forecast, Price & News

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Morphic in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" MORF shares.
View MORF analyst ratings or view top-rated stocks.

5 brokerages have issued twelve-month target prices for Morphic's shares. Their MORF share price forecasts range from $56.00 to $106.00. On average, they predict the company's stock price to reach $73.43 in the next year. This suggests a possible upside of 90.7% from the stock's current price.
View analysts price targets for MORF or view top-rated stocks among Wall Street analysts.

Morphic's stock was trading at $26.75 at the start of the year. Since then, MORF shares have increased by 43.9% and is now trading at $38.50.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our MORF earnings forecast.

Morphic Holding, Inc. (NASDAQ:MORF) posted its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by $0.02. Morphic had a negative trailing twelve-month return on equity of 27.71% and a negative net margin of 92.38%.

ETFs with the largest weight of Morphic (NASDAQ:MORF) stock in their portfolio include Alpha Architect U.S. Quantitative Momentum ETF (QMOM), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).First Trust Small Cap Growth AlphaDEX Fund (FYC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Morphic investors own include Fulcrum Therapeutics (FULC), Akero Therapeutics (AKRO), AVEO Pharmaceuticals (AVEO), Atreca (BCEL), CymaBay Therapeutics (CBAY), Chiasma (CHMA), Clovis Oncology (CLVS), Gritstone bio (GRTS), Idera Pharmaceuticals (IDRA) and Kaleido Biosciences (KLDO).

(MORF) raised $75 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Cowen, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO.

Morphic trades on the NASDAQ under the ticker symbol "MORF."

Morphic's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.74%), State Street Corp (3.62%), Alliancebernstein L.P. (2.42%), Holocene Advisors LP (1.77%), Geode Capital Management LLC (1.38%) and Driehaus Capital Management LLC (1.19%). Insiders that own company stock include Alexey Lugovskoy, Amir Nashat, Bruce Rogers, Fund V Gp LP Omega, Fund V LP Omega, Marc Schegerin, Peter Linde, Praveen P Tipirneni, Robert E Farrell Jr, Robert E Farrell, Jr, Timothy A Springer, Timothy A Springer and William Devaul.
View institutional ownership trends.

Shares of MORF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of MORF stock can currently be purchased for approximately $38.50.

Morphic (NASDAQ:MORF) has a market capitalization of $1.84 billion and generates $70.81 million in revenue each year. The company earns $-59,040,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis.

The company employs 110 workers across the globe.

Morphic's mailing address is 35 Gatehouse Drive A2, Waltham MA, 02451. The official website for the company is www.morphictx.com. The company can be reached via phone at (781) 996-0955.